Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
16.67
+0.19 (1.15%)
May 13, 2026, 4:00 PM EDT - Market closed
Theravance Biopharma Employees
Theravance Biopharma had 90 employees as of December 31, 2025. The number of employees decreased by 7 or -7.22% compared to the previous year.
Employees
90
Change (1Y)
-7
Growth (1Y)
-7.22%
Revenue / Employee
$1,219,722
Profits / Employee
$1,272,678
Market Cap
859.39M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 90 | -7 | -7.22% | 90 | 0 |
| Dec 31, 2024 | 97 | -2 | -2.02% | 97 | 0 |
| Dec 31, 2023 | 99 | -12 | -10.81% | 99 | 0 |
| Dec 31, 2022 | 111 | -48 | -30.19% | 111 | 0 |
| Dec 31, 2021 | 159 | -200 | -55.71% | 158 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Kura Oncology | 260 |
| ARS Pharmaceuticals | 163 |
| Sana Biotechnology | 142 |
| Absci | 140 |
| Alpha Tau Medical | 121 |
| Janux Therapeutics | 108 |
| Annexon | 93 |
| Vor Biopharma | 76 |
TBPH News
- 6 days ago - Theravance Biopharma reports Q1 EPS (10c) vs. (17c) last year - TheFly
- 6 days ago - Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update - PRNewsWire
- 5 weeks ago - Theravance Biopharma price target raised to $17 from $14 at B. Riley - TheFly
- 7 weeks ago - Theravance Biopharma price target raised to $15 from $13 at TD Cowen - TheFly
- 7 weeks ago - Theravance Biopharma reports Q4 EPS $1.15, consensus $1.10 - TheFly
- 7 weeks ago - Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Theravance Biopharma options imply 3.2% move in share price post-earnings - TheFly
- 2 months ago - Theravance Biopharma downgraded to Perform from Outperform at Oppenheimer - TheFly